- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.03. | Prenetics: Aktienrückkaufprogramm über 40 Mio. USD treibt Kurs an | 2 | Investing.com Deutsch | ||
| 06.03. | Prenetics Global Board Authorizes Share Repurchase Program | - | RTTNews | ||
| 06.03. | Prenetics rises on $40M share buyback program | 1 | Seeking Alpha | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 06.03. | Prenetics announces $40M share buyback program | 1 | Investing.com | ||
| 06.03. | Prenetics Global Limited: Prenetics Authorizes $40 Million Share Repurchase Program | 1 | GlobeNewswire (USA) | ||
| 03.03. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.03. | Prenetics executives purchase $1.3M in company shares | 3 | Investing.com | ||
| 23.02. | Prenetics Global Limited: Prenetics Launches IM8 Daily Ultimate Essentials PRO - A Clinical Formula with Two New Flavours | 1 | GlobeNewswire (USA) | ||
| 18.02. | Prenetics veräußert Insighta-Beteiligung für 70 Millionen US-Dollar an Tencent | 15 | Investing.com Deutsch | ||
| 18.02. | Prenetics Global Limited: Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR in 12 Months, Revenue Surges 480% YoY | 650 | GlobeNewswire (Europe) | Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic... ► Artikel lesen | |
| 17.02. | Prenetics appoints longevity expert Dr. Darshan Shah to board | 3 | Investing.com | ||
| 17.02. | Prenetics Global Limited: Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors | 746 | GlobeNewswire (Europe) | Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| 17.02. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.02. | Prenetics Global Limited: Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity | 904 | GlobeNewswire (Europe) | Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026... ► Artikel lesen | |
| 15.02. | Quant snapshot: IAMGOLD, Prenetics lead strong buys as Sol Strategies, Endava lag | 18 | Seeking Alpha | ||
| 13.02. | Prenetics Global Limited: Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder | 1 | GlobeNewswire (USA) | ||
| 11.02. | Roth/MKM initiates Prenetics stock with Buy rating on IM8 supplement success | 1 | Investing.com | ||
| 11.02. | Roth/MKM stuft Prenetics mit "Buy" ein - Erfolg von IM8-Nahrungsergänzungsmittel als Treiber | 2 | Investing.com Deutsch | ||
| 06.01. | Prenetics divests 3PL distribution business in all-stock deal valued at up to $13M | 2 | Seeking Alpha | ||
| 05.01. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS | 632,00 | -0,32 % | EQS-News: Formycon AG: Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit Regeneron und Bayer | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| CANSINO BIOLOGICS | 3,602 | -2,81 % | CANSINOBIO (06185): NOTICE OF BOARD MEETING | ||
| SINO BIOPHARM | 0,660 | +2,26 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TRD221 "COMPLEMENT PROTEIN MODULATOR" APPROVED BY THE NMPA | ||
| GUARDANT HEALTH | 75,40 | +2,28 % | Cathie Wood's ARK sells Guardant Health stock, buys Arcturus Therapeutics | ||
| BIO-TECHNE | 44,200 | -0,90 % | How Is Bio-Techne's Stock Performance Compared to Other Biotechnology Stocks | ||
| GENSCRIPT BIOTECH | 1,199 | -2,44 % | GenScript Biotech Corporation: GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth | Group PerformanceRevenue: US$959.5 million, +61.4% year-on-yearGross profit: US$553.2 million, +103.3% year-on-yearAdjusted net profit: US$230.3 million, +285.0% year-on-yearBusiness Units'... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 9,000 | +3,45 % | CMBI Recommends INNOVENT BIO/3SBIO, Anticipates Fundamentals of CN Healthcare Industry to Accelerate Improvement | ||
| QUANTUM-SI | 0,856 | -1,65 % | Quantum-Si outlines $1M 2026 revenue target and $425,000 Proteus list price as company prepares for major platform transition | ||
| ORIGIN AGRITECH | 0,945 | 0,00 % | Origin Agritech Limited: Origin Agritech Announces Fiscal Year 2025 Results | Announces Filing of Annual Report on Form 20-F for Fiscal Year 2025
BEIJING, Jan. 30, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or... ► Artikel lesen | |
| SCILEX | 6,480 | -1,22 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.02.2026 | The following instruments on XETRA do have their first trading 10.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.02.2026
Aktien
1 CNE100006V73 Auntea Jenny (Shanghai)... ► Artikel lesen | |
| AKESO | 12,300 | 0,00 % | Akeso, Inc.: Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance | HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 27,750 | -0,50 % | UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry | ||
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen |
Das Unternehmen PRENETICS GLOBAL LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,57 % bei einem Aktienkurs von 19,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.